<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03043209</url>
  </required_header>
  <id_info>
    <org_study_id>17-090</org_study_id>
    <nct_id>NCT03043209</nct_id>
  </id_info>
  <brief_title>Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy</brief_title>
  <official_title>Genomic Sequencing in Patients With Hypertrophic Cardiomyopathy Undergoing Septal Myectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators aim to use comparative exome and/or genome sequencing to discover causative&#xD;
      molecular lesions for phenotypes hypothesized to be caused by somatic mutations. For this&#xD;
      study, investigators have targeted hypertrophic cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis is that sporadic or simplex occurrences of what are typically autosomal&#xD;
      dominantly inherited diseases can instead be caused my mosaic mutations, specifically,&#xD;
      mutations in the heart itself.&#xD;
&#xD;
      This hypothesis mandates that investigators sequence both affected and unaffected tissues,&#xD;
      which in this case, investigators will construe to be peripheral blood DNA and discarded&#xD;
      myocardium from cardiac procedures.&#xD;
&#xD;
      Eligible individuals will first undergo informed consent to be part of the study prior to&#xD;
      their scheduled myomectomy. The study participants will also have phlebotomy for research&#xD;
      samples.&#xD;
&#xD;
      The NIH Intramural Sequencing Center (NISC) will perform paired exome or genome sequencing&#xD;
      and we will first screen for germline mutations in known cardiomyopathy genes that meet ACMG&#xD;
      standards of likely pathogenic or pathogenic.&#xD;
&#xD;
      Then, if this is negative, investigators will screen for sequence variants that are present&#xD;
      in cardiac tissue but absent in the blood DNA. Investigators will also screen blood DNA for&#xD;
      secondary findings in genes recommended for annotation and results return by the ACMG and&#xD;
      sequence variants deemed clinically relevant in this gene set will be validated in a&#xD;
      CLIA-certified laboratory and the results returned to that participant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">December 4, 2021</completion_date>
  <primary_completion_date type="Actual">December 4, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic causes of HCM in patients without a strong family history of the condition</measure>
    <time_frame>one year</time_frame>
    <description>The investigators will use DNA testing technology called &quot;genomic sequencing&quot;</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Genetic Disease</condition>
  <condition>Gene Product Sequence Variation</condition>
  <arm_group>
    <arm_group_label>Genomic sequencing</arm_group_label>
    <description>Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genomic sequencing</intervention_name>
    <description>Genomic sequencing of DNA in Blood sample and myectomy tissue</description>
    <arm_group_label>Genomic sequencing</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      leftover of myectomy tissue and peripheral blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        18 years and older, scheduled for septal myectomy and no family history of HCM&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is 18 years and older has a clinical diagnosis of hypertrophic cardiomyopathy.&#xD;
&#xD;
          -  Patient scheduled for clinically-indicated myomectomy.&#xD;
&#xD;
          -  Patient has a negative family history of hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Patient is willing to receive results of secondary variant screen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milind Desai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Milind Desai</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

